Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 118 | 2024 | 17352 | 4.770 |
Why?
|
HIV-1 | 67 | 2024 | 6863 | 4.630 |
Why?
|
Anti-Retroviral Agents | 38 | 2024 | 1784 | 3.420 |
Why?
|
Viral Load | 45 | 2024 | 3332 | 2.730 |
Why?
|
Anti-HIV Agents | 41 | 2023 | 4527 | 2.510 |
Why?
|
Proviruses | 12 | 2024 | 313 | 2.090 |
Why?
|
Viremia | 19 | 2024 | 707 | 1.820 |
Why?
|
CD4 Lymphocyte Count | 35 | 2021 | 2571 | 1.790 |
Why?
|
CD4-Positive T-Lymphocytes | 26 | 2023 | 4369 | 1.430 |
Why?
|
Acquired Immunodeficiency Syndrome | 10 | 2022 | 2199 | 1.430 |
Why?
|
Antiretroviral Therapy, Highly Active | 19 | 2021 | 1897 | 1.390 |
Why?
|
RNA, Viral | 25 | 2021 | 2846 | 1.230 |
Why?
|
DNA, Viral | 13 | 2023 | 2202 | 1.160 |
Why?
|
AIDS Vaccines | 9 | 2016 | 896 | 1.070 |
Why?
|
HIV-2 | 2 | 2020 | 156 | 1.030 |
Why?
|
Virus Latency | 11 | 2024 | 363 | 1.000 |
Why?
|
Antiviral Agents | 14 | 2024 | 3060 | 0.990 |
Why?
|
Drug Resistance, Viral | 10 | 2021 | 862 | 0.930 |
Why?
|
Reverse Transcriptase Inhibitors | 5 | 2020 | 621 | 0.920 |
Why?
|
AIDS-Related Opportunistic Infections | 5 | 2020 | 662 | 0.840 |
Why?
|
HIV Seropositivity | 6 | 2022 | 960 | 0.820 |
Why?
|
Pyrrolidinones | 3 | 2012 | 116 | 0.800 |
Why?
|
Hepatitis B Antibodies | 4 | 2009 | 155 | 0.800 |
Why?
|
Hepatitis C | 12 | 2019 | 1584 | 0.800 |
Why?
|
Toxoplasmosis, Cerebral | 1 | 2020 | 19 | 0.730 |
Why?
|
nef Gene Products, Human Immunodeficiency Virus | 4 | 2017 | 148 | 0.710 |
Why?
|
HIV Envelope Protein gp41 | 3 | 2015 | 303 | 0.690 |
Why?
|
Cough | 1 | 2023 | 594 | 0.680 |
Why?
|
Hepatitis B Vaccines | 3 | 2017 | 178 | 0.650 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 2 | 2020 | 206 | 0.650 |
Why?
|
HIV | 8 | 2023 | 1582 | 0.620 |
Why?
|
Gait Disorders, Neurologic | 1 | 2020 | 240 | 0.600 |
Why?
|
Dyspnea | 3 | 2023 | 1347 | 0.590 |
Why?
|
CD8-Positive T-Lymphocytes | 19 | 2024 | 4580 | 0.580 |
Why?
|
Syphilis | 3 | 2018 | 243 | 0.560 |
Why?
|
Humans | 175 | 2024 | 761572 | 0.560 |
Why?
|
Withholding Treatment | 4 | 2019 | 617 | 0.550 |
Why?
|
Lymphocyte Activation | 12 | 2023 | 5485 | 0.550 |
Why?
|
HLA-B Antigens | 2 | 2015 | 317 | 0.540 |
Why?
|
HLA-C Antigens | 2 | 2015 | 140 | 0.520 |
Why?
|
Hepatitis B Core Antigens | 3 | 2005 | 90 | 0.510 |
Why?
|
Salvage Therapy | 2 | 2020 | 1264 | 0.510 |
Why?
|
HLA-A Antigens | 2 | 2015 | 223 | 0.510 |
Why?
|
Ritonavir | 5 | 2022 | 329 | 0.510 |
Why?
|
Epidemics | 1 | 2021 | 512 | 0.500 |
Why?
|
Treponema pallidum | 1 | 2014 | 47 | 0.480 |
Why?
|
Pandemics | 10 | 2023 | 8656 | 0.470 |
Why?
|
Hepatitis B | 3 | 2005 | 705 | 0.460 |
Why?
|
Dendritic Cells | 4 | 2016 | 2747 | 0.460 |
Why?
|
Lymphadenitis | 1 | 2014 | 99 | 0.450 |
Why?
|
Plasma | 4 | 2021 | 586 | 0.450 |
Why?
|
Histone Deacetylase Inhibitors | 3 | 2024 | 774 | 0.430 |
Why?
|
Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 61 | 0.430 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3086 | 0.420 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3206 | 0.420 |
Why?
|
HIV Antibodies | 5 | 2022 | 1303 | 0.420 |
Why?
|
Hydroxylamines | 2 | 2022 | 40 | 0.400 |
Why?
|
Lymphocyte Subsets | 1 | 2013 | 309 | 0.400 |
Why?
|
Cytidine | 2 | 2022 | 64 | 0.400 |
Why?
|
Sarcoma, Kaposi | 2 | 2017 | 374 | 0.380 |
Why?
|
Adrenal Insufficiency | 1 | 2013 | 194 | 0.380 |
Why?
|
HIV Protease Inhibitors | 1 | 2013 | 432 | 0.370 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 5 | 2017 | 133 | 0.370 |
Why?
|
Adrenal Glands | 1 | 2013 | 552 | 0.360 |
Why?
|
Pituitary Gland | 1 | 2013 | 635 | 0.360 |
Why?
|
HIV Integrase Inhibitors | 2 | 2014 | 165 | 0.350 |
Why?
|
Adenosine Monophosphate | 2 | 2022 | 231 | 0.350 |
Why?
|
Peptide Fragments | 4 | 2015 | 5112 | 0.340 |
Why?
|
Hepatitis B virus | 2 | 2003 | 528 | 0.340 |
Why?
|
Canarypox virus | 1 | 2009 | 10 | 0.340 |
Why?
|
Pharmaceutical Preparations | 3 | 2023 | 1089 | 0.330 |
Why?
|
Virus Replication | 5 | 2019 | 2435 | 0.330 |
Why?
|
Alanine | 2 | 2022 | 609 | 0.320 |
Why?
|
Adult | 63 | 2024 | 221203 | 0.320 |
Why?
|
Male | 76 | 2024 | 360842 | 0.310 |
Why?
|
Hypothalamus | 1 | 2013 | 999 | 0.300 |
Why?
|
Secondary Prevention | 1 | 2014 | 1475 | 0.290 |
Why?
|
Thrombosis | 1 | 2021 | 2942 | 0.290 |
Why?
|
Female | 71 | 2024 | 392686 | 0.290 |
Why?
|
Middle Aged | 58 | 2024 | 220920 | 0.290 |
Why?
|
Diagnosis, Differential | 10 | 2023 | 12975 | 0.280 |
Why?
|
Interferons | 2 | 2007 | 706 | 0.280 |
Why?
|
Organic Chemicals | 1 | 2007 | 210 | 0.280 |
Why?
|
National Institutes of Health (U.S.) | 3 | 2024 | 793 | 0.260 |
Why?
|
Metabolic Diseases | 1 | 2012 | 683 | 0.250 |
Why?
|
JC Virus | 3 | 2011 | 87 | 0.240 |
Why?
|
Hypertension, Portal | 1 | 2006 | 226 | 0.230 |
Why?
|
Drug Therapy, Combination | 8 | 2020 | 6312 | 0.230 |
Why?
|
Adrenal Cortex Hormones | 1 | 2013 | 1881 | 0.230 |
Why?
|
Killer Cells, Natural | 5 | 2024 | 2201 | 0.230 |
Why?
|
Hepatitis B, Chronic | 2 | 2005 | 410 | 0.230 |
Why?
|
Cyclohexanes | 2 | 2015 | 152 | 0.220 |
Why?
|
Drug Resistance, Multiple, Viral | 1 | 2003 | 53 | 0.220 |
Why?
|
Intracranial Hemorrhage, Traumatic | 1 | 2024 | 54 | 0.220 |
Why?
|
Inflammation | 4 | 2022 | 10773 | 0.220 |
Why?
|
RNA, Messenger | 3 | 2016 | 12794 | 0.220 |
Why?
|
Lymph Nodes | 1 | 2014 | 3466 | 0.210 |
Why?
|
Practice Guidelines as Topic | 5 | 2024 | 7391 | 0.210 |
Why?
|
Drug Combinations | 2 | 2022 | 2048 | 0.200 |
Why?
|
Liver Cirrhosis | 3 | 2007 | 1935 | 0.200 |
Why?
|
Glasgow Coma Scale | 1 | 2024 | 580 | 0.200 |
Why?
|
Antibodies, Neutralizing | 2 | 2022 | 1943 | 0.200 |
Why?
|
HIV Antigens | 2 | 2021 | 325 | 0.190 |
Why?
|
Skin Diseases, Viral | 1 | 2021 | 26 | 0.190 |
Why?
|
Tranexamic Acid | 1 | 2024 | 176 | 0.190 |
Why?
|
Lactams | 1 | 2022 | 156 | 0.190 |
Why?
|
Depsipeptides | 1 | 2021 | 95 | 0.180 |
Why?
|
Antifibrinolytic Agents | 1 | 2024 | 292 | 0.180 |
Why?
|
Tamoxifen | 2 | 2022 | 965 | 0.180 |
Why?
|
RNA | 4 | 2023 | 2726 | 0.180 |
Why?
|
Interferon-alpha | 2 | 2024 | 921 | 0.180 |
Why?
|
Opportunistic Infections | 1 | 2023 | 376 | 0.180 |
Why?
|
Communicable Diseases, Emerging | 1 | 2022 | 148 | 0.180 |
Why?
|
Leucine | 1 | 2022 | 548 | 0.180 |
Why?
|
Streptococcus pyogenes | 1 | 2003 | 292 | 0.180 |
Why?
|
Purpura | 1 | 2021 | 117 | 0.180 |
Why?
|
T-Lymphocytes, Cytotoxic | 4 | 2023 | 1784 | 0.170 |
Why?
|
Proline | 1 | 2022 | 457 | 0.170 |
Why?
|
Abdominal Injuries | 1 | 2023 | 360 | 0.170 |
Why?
|
HIV Long-Term Survivors | 2 | 2018 | 121 | 0.170 |
Why?
|
Pressure Ulcer | 1 | 2021 | 157 | 0.170 |
Why?
|
Immunomodulation | 1 | 2023 | 549 | 0.170 |
Why?
|
Enzyme-Linked Immunospot Assay | 2 | 2017 | 123 | 0.160 |
Why?
|
Liver Diseases | 1 | 2007 | 1298 | 0.160 |
Why?
|
DNA | 3 | 2024 | 7213 | 0.160 |
Why?
|
Tuberculosis, Cutaneous | 1 | 2018 | 17 | 0.160 |
Why?
|
New York City | 1 | 2021 | 731 | 0.160 |
Why?
|
Nitriles | 2 | 2022 | 971 | 0.160 |
Why?
|
Hepacivirus | 5 | 2006 | 1336 | 0.160 |
Why?
|
South Africa | 5 | 2023 | 1843 | 0.160 |
Why?
|
Health Care Rationing | 1 | 2022 | 437 | 0.160 |
Why?
|
Triazoles | 2 | 2015 | 903 | 0.160 |
Why?
|
Estrogen Receptor alpha | 1 | 2022 | 583 | 0.150 |
Why?
|
Interleukin-6 | 2 | 2023 | 3208 | 0.150 |
Why?
|
Streptococcal Infections | 1 | 2003 | 617 | 0.150 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2003 | 664 | 0.150 |
Why?
|
Hepatitis A Vaccines | 1 | 2017 | 26 | 0.150 |
Why?
|
Exanthema | 2 | 2021 | 503 | 0.150 |
Why?
|
Mycobacterium Infections | 1 | 2018 | 122 | 0.150 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 250 | 0.150 |
Why?
|
Tetanus Toxoid | 1 | 2017 | 189 | 0.140 |
Why?
|
Immunologic Memory | 3 | 2024 | 1359 | 0.140 |
Why?
|
Ribavirin | 3 | 2007 | 395 | 0.140 |
Why?
|
Parotid Gland | 1 | 2018 | 175 | 0.140 |
Why?
|
Crowding | 1 | 2018 | 142 | 0.140 |
Why?
|
Hepatitis C, Chronic | 1 | 2005 | 1032 | 0.140 |
Why?
|
Mycobacterium | 1 | 2018 | 251 | 0.140 |
Why?
|
Wounds, Nonpenetrating | 1 | 2023 | 807 | 0.140 |
Why?
|
Immunotherapy | 2 | 2003 | 4652 | 0.140 |
Why?
|
Antibodies, Viral | 4 | 2022 | 3156 | 0.140 |
Why?
|
AIDS Dementia Complex | 1 | 2017 | 153 | 0.130 |
Why?
|
Shock, Septic | 1 | 2003 | 768 | 0.130 |
Why?
|
Injections, Intradermal | 1 | 2016 | 116 | 0.130 |
Why?
|
Virus Integration | 1 | 2018 | 304 | 0.130 |
Why?
|
Glomerulosclerosis, Focal Segmental | 1 | 2019 | 335 | 0.130 |
Why?
|
Burkitt Lymphoma | 1 | 2018 | 335 | 0.130 |
Why?
|
Specialization | 1 | 2020 | 778 | 0.130 |
Why?
|
Androgen Antagonists | 1 | 2024 | 1410 | 0.130 |
Why?
|
Cohort Studies | 9 | 2024 | 41493 | 0.120 |
Why?
|
Internet | 1 | 2007 | 3093 | 0.120 |
Why?
|
Leukocytes, Mononuclear | 3 | 2018 | 1844 | 0.120 |
Why?
|
Bartonella Infections | 1 | 2014 | 21 | 0.120 |
Why?
|
Remission Induction | 1 | 2021 | 2397 | 0.120 |
Why?
|
Clozapine | 2 | 2009 | 504 | 0.120 |
Why?
|
Thailand | 1 | 2015 | 287 | 0.120 |
Why?
|
Phylogeny | 3 | 2018 | 2811 | 0.120 |
Why?
|
Shock, Hemorrhagic | 1 | 2016 | 223 | 0.120 |
Why?
|
Hair | 1 | 2018 | 498 | 0.120 |
Why?
|
Tenosynovitis | 1 | 2014 | 57 | 0.120 |
Why?
|
Bacterial Translocation | 1 | 2014 | 73 | 0.120 |
Why?
|
Immunization | 2 | 2016 | 1227 | 0.120 |
Why?
|
Skin | 3 | 2013 | 4484 | 0.110 |
Why?
|
Cardiovascular Diseases | 4 | 2024 | 15501 | 0.110 |
Why?
|
Health Personnel | 1 | 2007 | 3335 | 0.110 |
Why?
|
Skin Neoplasms | 1 | 2013 | 5821 | 0.110 |
Why?
|
Communicable Disease Control | 1 | 2020 | 846 | 0.110 |
Why?
|
Vaccination | 3 | 2021 | 3384 | 0.110 |
Why?
|
Outpatients | 1 | 2022 | 1597 | 0.110 |
Why?
|
Cryptococcosis | 1 | 2014 | 104 | 0.110 |
Why?
|
Publishing | 1 | 2021 | 833 | 0.110 |
Why?
|
Histocompatibility Testing | 1 | 2015 | 712 | 0.110 |
Why?
|
Polyamines | 1 | 2014 | 133 | 0.110 |
Why?
|
T-Lymphocytes | 4 | 2021 | 10194 | 0.110 |
Why?
|
Genetic Predisposition to Disease | 1 | 2015 | 17904 | 0.110 |
Why?
|
Aged | 18 | 2024 | 169310 | 0.110 |
Why?
|
Polymerase Chain Reaction | 4 | 2020 | 6075 | 0.110 |
Why?
|
Lymphatic Diseases | 1 | 2014 | 320 | 0.110 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2014 | 242 | 0.110 |
Why?
|
Brain Diseases | 1 | 2022 | 1545 | 0.100 |
Why?
|
Postpartum Period | 1 | 2019 | 1173 | 0.100 |
Why?
|
Clinical Trials as Topic | 3 | 2016 | 8002 | 0.100 |
Why?
|
Trauma Centers | 1 | 2018 | 937 | 0.100 |
Why?
|
Emergency Medical Services | 1 | 2024 | 1923 | 0.100 |
Why?
|
Thromboplastin | 1 | 2014 | 286 | 0.100 |
Why?
|
Headache | 1 | 2020 | 1256 | 0.100 |
Why?
|
Longitudinal Studies | 7 | 2024 | 14607 | 0.100 |
Why?
|
HIV Long Terminal Repeat | 1 | 2012 | 85 | 0.100 |
Why?
|
Histones | 1 | 2022 | 2580 | 0.100 |
Why?
|
Oxazines | 1 | 2014 | 350 | 0.100 |
Why?
|
Hypersensitivity, Delayed | 1 | 2013 | 490 | 0.100 |
Why?
|
Herpes Zoster | 1 | 2014 | 253 | 0.100 |
Why?
|
Orthomyxoviridae | 1 | 2013 | 149 | 0.100 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2014 | 287 | 0.100 |
Why?
|
Gene Expression | 2 | 2015 | 7581 | 0.090 |
Why?
|
Ambulatory Care | 1 | 2022 | 2775 | 0.090 |
Why?
|
HIV Envelope Protein gp120 | 2 | 2014 | 914 | 0.090 |
Why?
|
Comorbidity | 4 | 2020 | 10508 | 0.090 |
Why?
|
Lipoproteins, LDL | 1 | 2014 | 642 | 0.090 |
Why?
|
Microbial Sensitivity Tests | 1 | 2017 | 1937 | 0.090 |
Why?
|
Patient Participation | 1 | 2020 | 1445 | 0.090 |
Why?
|
Risk Factors | 6 | 2023 | 74213 | 0.090 |
Why?
|
Cost of Illness | 1 | 2020 | 1936 | 0.090 |
Why?
|
Tuberculosis | 2 | 2014 | 2017 | 0.090 |
Why?
|
Rifampin | 1 | 2012 | 339 | 0.090 |
Why?
|
Epitopes, T-Lymphocyte | 4 | 2013 | 828 | 0.090 |
Why?
|
Pityriasis Lichenoides | 1 | 2009 | 6 | 0.090 |
Why?
|
Genes, MHC Class I | 1 | 2010 | 235 | 0.090 |
Why?
|
Drug Administration Schedule | 4 | 2020 | 4853 | 0.090 |
Why?
|
Transfection | 2 | 2016 | 5774 | 0.090 |
Why?
|
Time Factors | 5 | 2021 | 39970 | 0.090 |
Why?
|
Length of Stay | 2 | 2021 | 6426 | 0.090 |
Why?
|
Logistic Models | 3 | 2020 | 13255 | 0.080 |
Why?
|
Acidosis, Lactic | 1 | 2011 | 146 | 0.080 |
Why?
|
Cholesterol, LDL | 2 | 2019 | 2382 | 0.080 |
Why?
|
Massachusetts | 2 | 2020 | 8830 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 4 | 2024 | 20571 | 0.080 |
Why?
|
Lung Neoplasms | 1 | 2013 | 13382 | 0.080 |
Why?
|
Inflammation Mediators | 1 | 2017 | 1886 | 0.080 |
Why?
|
Pyridones | 1 | 2014 | 809 | 0.080 |
Why?
|
Pregnancy | 5 | 2022 | 29876 | 0.080 |
Why?
|
Skin Diseases | 1 | 2017 | 1094 | 0.080 |
Why?
|
Gene Frequency | 1 | 2015 | 3606 | 0.080 |
Why?
|
Bone Resorption | 1 | 2012 | 723 | 0.080 |
Why?
|
Disease Progression | 6 | 2019 | 13510 | 0.070 |
Why?
|
Cardiovascular Agents | 1 | 2014 | 840 | 0.070 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2010 | 585 | 0.070 |
Why?
|
Gene Products, gag | 1 | 2008 | 312 | 0.070 |
Why?
|
Immunization Schedule | 1 | 2009 | 227 | 0.070 |
Why?
|
Transaminases | 1 | 2007 | 198 | 0.070 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2013 | 832 | 0.070 |
Why?
|
Interferon-gamma | 5 | 2021 | 3162 | 0.070 |
Why?
|
Uganda | 2 | 2021 | 1332 | 0.070 |
Why?
|
Alleles | 2 | 2015 | 6864 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 10212 | 0.070 |
Why?
|
Drug Costs | 2 | 2020 | 1183 | 0.070 |
Why?
|
Codon | 1 | 2008 | 601 | 0.070 |
Why?
|
Splenomegaly | 1 | 2006 | 189 | 0.070 |
Why?
|
Military Personnel | 1 | 2015 | 1246 | 0.070 |
Why?
|
Interleukin-12 | 1 | 2008 | 584 | 0.070 |
Why?
|
Leukocyte Count | 2 | 2007 | 1596 | 0.060 |
Why?
|
Lactic Acid | 1 | 2011 | 1139 | 0.060 |
Why?
|
Ambulatory Care Facilities | 1 | 2012 | 935 | 0.060 |
Why?
|
Advisory Committees | 2 | 2021 | 787 | 0.060 |
Why?
|
United States | 9 | 2024 | 72335 | 0.060 |
Why?
|
HLA-B8 Antigen | 1 | 2004 | 16 | 0.060 |
Why?
|
Hospitalization | 2 | 2022 | 10721 | 0.060 |
Why?
|
Medication Adherence | 2 | 2014 | 2176 | 0.060 |
Why?
|
Antipsychotic Agents | 2 | 2009 | 3067 | 0.060 |
Why?
|
Recurrence | 2 | 2016 | 8466 | 0.060 |
Why?
|
Boston | 3 | 2013 | 9326 | 0.060 |
Why?
|
Developing Countries | 2 | 2007 | 2885 | 0.060 |
Why?
|
Antigen Presentation | 1 | 2010 | 1251 | 0.060 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2019 | 2243 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9177 | 0.060 |
Why?
|
Immunotherapy, Active | 1 | 2004 | 59 | 0.060 |
Why?
|
Cytomegalovirus Infections | 2 | 2024 | 831 | 0.060 |
Why?
|
Receptors, CXCR4 | 1 | 2009 | 727 | 0.060 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 3245 | 0.060 |
Why?
|
Immunity | 2 | 2017 | 996 | 0.060 |
Why?
|
Young Adult | 12 | 2021 | 59255 | 0.060 |
Why?
|
Cross-Over Studies | 1 | 2010 | 2079 | 0.060 |
Why?
|
Biopsy | 3 | 2018 | 6766 | 0.060 |
Why?
|
Piperazines | 1 | 2014 | 2523 | 0.060 |
Why?
|
Severity of Illness Index | 2 | 2020 | 15843 | 0.060 |
Why?
|
Th1 Cells | 1 | 2008 | 1036 | 0.050 |
Why?
|
Kidney | 1 | 2019 | 7047 | 0.050 |
Why?
|
Th2 Cells | 1 | 2008 | 1060 | 0.050 |
Why?
|
Necrosis | 1 | 2007 | 1611 | 0.050 |
Why?
|
Viral Nonstructural Proteins | 1 | 2004 | 227 | 0.050 |
Why?
|
Retrospective Studies | 9 | 2024 | 80646 | 0.050 |
Why?
|
Quality Improvement | 1 | 2018 | 3801 | 0.050 |
Why?
|
Treatment Failure | 2 | 2021 | 2644 | 0.050 |
Why?
|
CD4-CD8 Ratio | 2 | 2015 | 114 | 0.050 |
Why?
|
STAT5 Transcription Factor | 1 | 2023 | 265 | 0.050 |
Why?
|
Interleukin-15 | 1 | 2023 | 185 | 0.050 |
Why?
|
Myeloid Cells | 1 | 2007 | 823 | 0.050 |
Why?
|
Survival Analysis | 1 | 2015 | 10090 | 0.050 |
Why?
|
Vaccines, Subunit | 2 | 2014 | 161 | 0.050 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2003 | 294 | 0.050 |
Why?
|
RNA, Ribosomal, 16S | 2 | 2018 | 1039 | 0.050 |
Why?
|
Papillomavirus Infections | 1 | 2014 | 1613 | 0.050 |
Why?
|
Radiography | 1 | 2013 | 6965 | 0.050 |
Why?
|
Education, Medical, Continuing | 1 | 2007 | 823 | 0.050 |
Why?
|
Physicians | 1 | 2020 | 4591 | 0.050 |
Why?
|
Directly Observed Therapy | 1 | 2002 | 139 | 0.050 |
Why?
|
Receptors, Natural Killer Cell | 1 | 2022 | 57 | 0.050 |
Why?
|
Fasciitis, Necrotizing | 1 | 2003 | 79 | 0.050 |
Why?
|
Fatigue | 1 | 2009 | 1552 | 0.050 |
Why?
|
HLA-DR Antigens | 2 | 2014 | 602 | 0.050 |
Why?
|
Genetic Variation | 2 | 2015 | 6567 | 0.050 |
Why?
|
Influenza, Human | 1 | 2013 | 1521 | 0.050 |
Why?
|
Child | 5 | 2022 | 80156 | 0.050 |
Why?
|
Anastomotic Leak | 1 | 2023 | 163 | 0.050 |
Why?
|
Transcription, Genetic | 1 | 2015 | 7593 | 0.050 |
Why?
|
Haplorhini | 1 | 2002 | 525 | 0.050 |
Why?
|
Cognition | 1 | 2019 | 6992 | 0.050 |
Why?
|
Positive Transcriptional Elongation Factor B | 1 | 2021 | 42 | 0.050 |
Why?
|
DNA, Bacterial | 2 | 2018 | 1479 | 0.050 |
Why?
|
Prostatic Neoplasms | 1 | 2024 | 11122 | 0.050 |
Why?
|
Demography | 1 | 2006 | 1648 | 0.050 |
Why?
|
Flow Cytometry | 2 | 2014 | 5869 | 0.050 |
Why?
|
Fomites | 1 | 2020 | 15 | 0.050 |
Why?
|
Receptors, IgG | 1 | 2024 | 559 | 0.050 |
Why?
|
Lectins, C-Type | 1 | 2024 | 585 | 0.050 |
Why?
|
Protein Biosynthesis | 1 | 2008 | 2112 | 0.050 |
Why?
|
T-Lymphocyte Subsets | 1 | 2009 | 1802 | 0.050 |
Why?
|
Alkynes | 1 | 2021 | 320 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2023 | 13642 | 0.040 |
Why?
|
Heterochromatin | 1 | 2023 | 293 | 0.040 |
Why?
|
Cyclopropanes | 1 | 2021 | 432 | 0.040 |
Why?
|
Prone Position | 1 | 2021 | 196 | 0.040 |
Why?
|
International Agencies | 1 | 2020 | 243 | 0.040 |
Why?
|
Fatty Liver | 1 | 2006 | 790 | 0.040 |
Why?
|
Benzoxazines | 1 | 2021 | 316 | 0.040 |
Why?
|
Case-Control Studies | 2 | 2015 | 22176 | 0.040 |
Why?
|
Treatment Outcome | 9 | 2024 | 64684 | 0.040 |
Why?
|
Schizophrenia | 2 | 2009 | 6937 | 0.040 |
Why?
|
Double-Blind Method | 2 | 2012 | 12341 | 0.040 |
Why?
|
Prospective Studies | 5 | 2019 | 54426 | 0.040 |
Why?
|
Anastomosis, Surgical | 1 | 2023 | 983 | 0.040 |
Why?
|
Cell Proliferation | 3 | 2012 | 10448 | 0.040 |
Why?
|
Antidepressive Agents | 1 | 2012 | 2897 | 0.040 |
Why?
|
Pain | 1 | 2014 | 5073 | 0.040 |
Why?
|
Serologic Tests | 1 | 2021 | 381 | 0.040 |
Why?
|
Granzymes | 1 | 2021 | 277 | 0.040 |
Why?
|
AIDS-Associated Nephropathy | 1 | 2019 | 34 | 0.040 |
Why?
|
Lentivirus | 1 | 2022 | 508 | 0.040 |
Why?
|
Cross-Sectional Studies | 5 | 2022 | 26127 | 0.040 |
Why?
|
Equipment Contamination | 1 | 2020 | 182 | 0.040 |
Why?
|
Molecular Sequence Data | 5 | 2014 | 17635 | 0.040 |
Why?
|
Hospitals, Urban | 1 | 2021 | 500 | 0.040 |
Why?
|
Mycolic Acids | 1 | 2018 | 54 | 0.040 |
Why?
|
Referral and Consultation | 1 | 2012 | 3600 | 0.040 |
Why?
|
Defective Viruses | 1 | 2018 | 89 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2022 | 36429 | 0.040 |
Why?
|
Obesity | 1 | 2021 | 12947 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7879 | 0.040 |
Why?
|
Fees, Pharmaceutical | 1 | 2018 | 66 | 0.040 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 2 | 2013 | 369 | 0.040 |
Why?
|
Base Composition | 1 | 2018 | 290 | 0.040 |
Why?
|
Herpesvirus 4, Human | 2 | 2017 | 1078 | 0.040 |
Why?
|
Monocytes | 1 | 2007 | 2570 | 0.040 |
Why?
|
Disease Reservoirs | 1 | 2018 | 121 | 0.040 |
Why?
|
Polypharmacy | 1 | 2020 | 306 | 0.040 |
Why?
|
Receptors, Immunologic | 1 | 2024 | 1410 | 0.040 |
Why?
|
Drug Substitution | 1 | 2020 | 290 | 0.040 |
Why?
|
Bacterial Typing Techniques | 1 | 2018 | 263 | 0.040 |
Why?
|
Aerosols | 1 | 2020 | 635 | 0.040 |
Why?
|
Biological Evolution | 1 | 2003 | 1071 | 0.040 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2022 | 2547 | 0.040 |
Why?
|
Immune Evasion | 1 | 2021 | 363 | 0.040 |
Why?
|
Sexual Partners | 1 | 2022 | 796 | 0.040 |
Why?
|
Texas | 1 | 2018 | 404 | 0.040 |
Why?
|
Evidence-Based Medicine | 2 | 2021 | 3688 | 0.030 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2018 | 410 | 0.030 |
Why?
|
Patient Transfer | 1 | 2024 | 794 | 0.030 |
Why?
|
Italy | 1 | 2018 | 842 | 0.030 |
Why?
|
Pancytopenia | 1 | 2017 | 102 | 0.030 |
Why?
|
Aged, 80 and over | 3 | 2024 | 58986 | 0.030 |
Why?
|
Chronic Disease | 3 | 2012 | 9319 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2018 | 4740 | 0.030 |
Why?
|
Post-Exposure Prophylaxis | 1 | 2016 | 110 | 0.030 |
Why?
|
Colon | 1 | 2023 | 1792 | 0.030 |
Why?
|
Confusion | 1 | 2017 | 278 | 0.030 |
Why?
|
Interprofessional Relations | 1 | 2021 | 990 | 0.030 |
Why?
|
Ligands | 1 | 2022 | 3272 | 0.030 |
Why?
|
Amino Acid Sequence | 4 | 2009 | 13446 | 0.030 |
Why?
|
Lung | 1 | 2013 | 10002 | 0.030 |
Why?
|
Genome, Viral | 1 | 2018 | 667 | 0.030 |
Why?
|
Africa South of the Sahara | 1 | 2017 | 744 | 0.030 |
Why?
|
Emergency Treatment | 1 | 2018 | 496 | 0.030 |
Why?
|
Gene Products, tat | 1 | 2014 | 111 | 0.030 |
Why?
|
Drug Therapy | 1 | 2017 | 503 | 0.030 |
Why?
|
Drug Approval | 1 | 2021 | 814 | 0.030 |
Why?
|
Intestines | 1 | 2023 | 1909 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2022 | 1664 | 0.030 |
Why?
|
Pyridazines | 1 | 2015 | 202 | 0.030 |
Why?
|
Efficiency, Organizational | 1 | 2018 | 695 | 0.030 |
Why?
|
Brain | 1 | 2020 | 27120 | 0.030 |
Why?
|
Social Stigma | 1 | 2020 | 769 | 0.030 |
Why?
|
DNA, Ribosomal | 1 | 2014 | 300 | 0.030 |
Why?
|
Aging | 1 | 2012 | 8711 | 0.030 |
Why?
|
Membrane Glycoproteins | 2 | 2014 | 3701 | 0.030 |
Why?
|
Intubation, Intratracheal | 1 | 2021 | 1333 | 0.030 |
Why?
|
Nucleic Acid Hybridization | 1 | 2014 | 1302 | 0.030 |
Why?
|
Cytokines | 2 | 2018 | 7396 | 0.030 |
Why?
|
Coronary Artery Disease | 1 | 2012 | 6403 | 0.030 |
Why?
|
Genotype | 2 | 2006 | 12990 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 2017 | 756 | 0.030 |
Why?
|
Delphi Technique | 1 | 2016 | 846 | 0.030 |
Why?
|
HLA-A2 Antigen | 1 | 2013 | 211 | 0.030 |
Why?
|
Forecasting | 1 | 2002 | 2928 | 0.030 |
Why?
|
Patient Care Team | 1 | 2024 | 2521 | 0.030 |
Why?
|
Immunotherapy, Adoptive | 1 | 2022 | 1469 | 0.030 |
Why?
|
Patient Compliance | 1 | 2002 | 2690 | 0.030 |
Why?
|
Antibiotics, Antitubercular | 1 | 2012 | 99 | 0.020 |
Why?
|
Linear Models | 2 | 2014 | 5872 | 0.020 |
Why?
|
Resuscitation | 1 | 2016 | 673 | 0.020 |
Why?
|
Depression | 1 | 2012 | 8124 | 0.020 |
Why?
|
Viral Matrix Proteins | 1 | 2013 | 196 | 0.020 |
Why?
|
Face | 1 | 2018 | 1026 | 0.020 |
Why?
|
Liver | 1 | 2007 | 7529 | 0.020 |
Why?
|
Carcinoma, Basal Cell | 1 | 2017 | 560 | 0.020 |
Why?
|
tat Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 119 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2018 | 12059 | 0.020 |
Why?
|
Mass Screening | 1 | 2007 | 5428 | 0.020 |
Why?
|
Myocardial Infarction | 1 | 2012 | 11461 | 0.020 |
Why?
|
Quality of Life | 2 | 2023 | 13367 | 0.020 |
Why?
|
Vaccines, Synthetic | 1 | 2014 | 616 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1768 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2021 | 2691 | 0.020 |
Why?
|
Adolescent | 6 | 2019 | 88324 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 2 | 2012 | 6484 | 0.020 |
Why?
|
Wounds and Injuries | 1 | 2024 | 2491 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2003 | 8528 | 0.020 |
Why?
|
Frontal Lobe | 1 | 2017 | 1420 | 0.020 |
Why?
|
Anti-Bacterial Agents | 2 | 2014 | 7407 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2021 | 2759 | 0.020 |
Why?
|
Age Factors | 2 | 2020 | 18398 | 0.020 |
Why?
|
Telemedicine | 1 | 2007 | 3052 | 0.020 |
Why?
|
Melanoma | 1 | 2008 | 5709 | 0.020 |
Why?
|
Cost-Benefit Analysis | 2 | 2017 | 5492 | 0.020 |
Why?
|
Qualitative Research | 1 | 2020 | 3023 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2014 | 1869 | 0.020 |
Why?
|
MART-1 Antigen | 1 | 2008 | 65 | 0.020 |
Why?
|
Phenotype | 1 | 2007 | 16592 | 0.020 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 2009 | 85 | 0.020 |
Why?
|
Stem Cell Transplantation | 1 | 2017 | 1600 | 0.020 |
Why?
|
Diagnostic Tests, Routine | 1 | 2014 | 787 | 0.020 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2020 | 2151 | 0.020 |
Why?
|
Societies, Medical | 1 | 2020 | 3905 | 0.020 |
Why?
|
Neoplasms | 1 | 2017 | 22173 | 0.020 |
Why?
|
Interleukin-5 | 1 | 2008 | 269 | 0.020 |
Why?
|
HLA-B27 Antigen | 1 | 2007 | 63 | 0.020 |
Why?
|
Pharyngitis | 1 | 2009 | 220 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2014 | 2707 | 0.020 |
Why?
|
Mycobacterium tuberculosis | 1 | 2018 | 1914 | 0.020 |
Why?
|
Interleukin-2 | 1 | 2014 | 1889 | 0.020 |
Why?
|
Receptors, CCR5 | 1 | 2009 | 486 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2014 | 1265 | 0.020 |
Why?
|
Viral Structural Proteins | 1 | 2007 | 95 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2005 | 20099 | 0.020 |
Why?
|
Receptors, CCR7 | 1 | 2007 | 107 | 0.020 |
Why?
|
Jurkat Cells | 1 | 2008 | 740 | 0.020 |
Why?
|
HIV Core Protein p24 | 1 | 2006 | 245 | 0.020 |
Why?
|
Kidney Failure, Chronic | 1 | 2019 | 2472 | 0.020 |
Why?
|
Prevalence | 3 | 2009 | 15732 | 0.020 |
Why?
|
Lipopolysaccharides | 1 | 2014 | 2206 | 0.020 |
Why?
|
Adjuvants, Immunologic | 1 | 2012 | 1036 | 0.020 |
Why?
|
BK Virus | 1 | 2007 | 123 | 0.020 |
Why?
|
Nucleosides | 1 | 2006 | 131 | 0.020 |
Why?
|
Mutation | 3 | 2007 | 30054 | 0.020 |
Why?
|
Weight Loss | 1 | 2017 | 2684 | 0.020 |
Why?
|
Cell Death | 1 | 2011 | 1679 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2022 | 6485 | 0.020 |
Why?
|
Chest Pain | 1 | 2012 | 1091 | 0.020 |
Why?
|
Crohn Disease | 1 | 2018 | 2279 | 0.020 |
Why?
|
Cells, Cultured | 2 | 2013 | 18965 | 0.020 |
Why?
|
Health Promotion | 1 | 2017 | 2214 | 0.020 |
Why?
|
Neck | 1 | 2009 | 734 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2006 | 778 | 0.010 |
Why?
|
Cooperative Behavior | 1 | 2012 | 1505 | 0.010 |
Why?
|
Amino Acids | 1 | 2010 | 1718 | 0.010 |
Why?
|
Acute Disease | 2 | 2005 | 7237 | 0.010 |
Why?
|
Haplotypes | 1 | 2010 | 2713 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 2019 | 4235 | 0.010 |
Why?
|
Receptors, Chemokine | 1 | 2007 | 652 | 0.010 |
Why?
|
Virus Diseases | 1 | 2009 | 718 | 0.010 |
Why?
|
Immunoassay | 1 | 2006 | 745 | 0.010 |
Why?
|
Pyrimidines | 1 | 2015 | 3028 | 0.010 |
Why?
|
Infant | 1 | 2005 | 36192 | 0.010 |
Why?
|
Protein Conformation | 1 | 2010 | 3968 | 0.010 |
Why?
|
Incidence | 1 | 2021 | 21355 | 0.010 |
Why?
|
Fever | 1 | 2009 | 1618 | 0.010 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2012 | 6019 | 0.010 |
Why?
|
Research Design | 1 | 2017 | 6180 | 0.010 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2007 | 1349 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 3810 | 0.010 |
Why?
|
Protein Binding | 1 | 2013 | 9353 | 0.010 |
Why?
|
Coronary Angiography | 1 | 2012 | 4471 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 2008 | 1993 | 0.010 |
Why?
|
Host-Pathogen Interactions | 1 | 2009 | 1459 | 0.010 |
Why?
|
Epitopes | 1 | 2007 | 2503 | 0.010 |
Why?
|
Models, Molecular | 1 | 2010 | 5439 | 0.010 |
Why?
|
Amino Acid Substitution | 1 | 2004 | 1739 | 0.010 |
Why?
|
Polyethylene Glycols | 1 | 2005 | 1189 | 0.010 |
Why?
|
Kinetics | 1 | 2007 | 6374 | 0.010 |
Why?
|
Electrocardiography | 1 | 2012 | 6377 | 0.010 |
Why?
|
Risk Assessment | 1 | 2020 | 23996 | 0.010 |
Why?
|
Immunity, Innate | 1 | 2010 | 3066 | 0.010 |
Why?
|
Viral Proteins | 1 | 2005 | 1804 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39107 | 0.010 |
Why?
|
Mitochondria | 1 | 2011 | 3624 | 0.010 |
Why?
|
Life Expectancy | 1 | 2004 | 1242 | 0.010 |
Why?
|
Viral Vaccines | 1 | 2002 | 596 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2008 | 3617 | 0.010 |
Why?
|
Up-Regulation | 1 | 2005 | 4124 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2011 | 12463 | 0.010 |
Why?
|
Evolution, Molecular | 1 | 2004 | 1886 | 0.010 |
Why?
|
Pilot Projects | 1 | 2009 | 8633 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15266 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2005 | 6534 | 0.010 |
Why?
|
Prognosis | 1 | 2016 | 29629 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 2009 | 4758 | 0.010 |
Why?
|
Animals | 2 | 2004 | 168467 | 0.010 |
Why?
|
Body Mass Index | 1 | 2011 | 12954 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2010 | 12690 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2010 | 15936 | 0.010 |
Why?
|
Computer Simulation | 1 | 2004 | 6241 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2007 | 11530 | 0.010 |
Why?
|
Child, Preschool | 1 | 2007 | 42230 | 0.000 |
Why?
|